Rhenman & Partners Asset Management Ab Nuvalent, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $959 Million
- Q4 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Nuvalent, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 72,500 shares of NUVL stock, worth $5.63 Million. This represents 0.59% of its overall portfolio holdings.
Number of Shares
72,500
Previous 90,000
19.44%
Holding current value
$5.63 Million
Previous $9.21 Million
38.36%
% of portfolio
0.59%
Previous 0.77%
Shares
8 transactions
Others Institutions Holding NUVL
# of Institutions
232Shares Held
59MCall Options Held
834KPut Options Held
490K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.4 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$416 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$349 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$235 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$203 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.34B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...